stockrowNeurocrine Biosciences, Inc. (NBIX) vs Teva Pharmaceutical Industries Ltd. (TEVA)
- Neurocrine Biosciences, Inc. NBIX 160.47 −3.36%
- Teva Pharmaceutical Industries Ltd. TEVA 41.73 −0.29%
Neurocrine Biosciences, Inc. and Teva Pharmaceutical Industries Ltd. are both Drug Manufacturers Specialty & Generic companies. Teva Pharmaceutical Industries Ltd. is the larger, with a market value of $48.7B against $16.2B — 3.0× the size. Neurocrine Biosciences, Inc. trades at the lower P/E: 23.0× against 92.6×. Neurocrine Biosciences, Inc. grew revenue faster over the last twelve months: 38.0% against 2.71%. Neurocrine Biosciences, Inc. has the higher net margin (19.0% vs 2.94%) and the higher return on invested capital (17.7% vs 4.09%). Across the 22 metrics below, Neurocrine Biosciences, Inc. leads on 19 and Teva Pharmaceutical Industries Ltd. on 3.
Valuation
Profitability
| Metric | NBIX | TEVA | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | 97.75% | 53.51% | 53.51% |
| Operating margin | 23.96% | 7.84% | 0.00% |
| Net margin | 18.98% | 2.94% | (2.45%) |
| Free cash flow margin | 28.09% | 7.71% | 0.00% |
| Return on equity | 20.41% | 6.65% | (0.80%) |
| Return on assets | 14.20% | 1.27% | (1.67%) |
| Return on invested capital | 17.65% | 4.09% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack